Prevalence of autoantibodies against 3-DG-glycated H2A protein in type 2 diabetes
- Авторы: Ashraf J.1, Abdullah S.1, Ahmad S.2, Fatma S.3, Baig M.4, Iqbal J.5, Madkhali A.1, Jerah A.1
-
Учреждения:
- Faculty of Applied Medical Sciences
- Department of Biotechnology
- Faculty of Science
- Department of Medical Biotechnology
- Faculty of Medicine
- Выпуск: Том 82, № 5 (2017)
- Страницы: 579-586
- Раздел: Article
- URL: https://journals.rcsi.science/0006-2979/article/view/151377
- DOI: https://doi.org/10.1134/S0006297917050066
- ID: 151377
Цитировать
Аннотация
Advanced glycation end-products (AGEs) have been found to be critically involved in initiation or progression of diabetes secondary complications (nephropathy, retinopathy, neuropathy, and angiopathy). Various hyper-glycating carbonyl compounds such as 3-deoxyglucosone (3-DG) are produced in pathophysiological conditions that form AGEs in high quantity both in vivo and in vitro. In the first stage of this study, we glycated histone H2A protein by 3-DG, and the results showed the formation of various intermediates and AGEs as well as structural changes in the protein. In the second stage, we studied the immunogenicity of native and 3-DG-glycated H2A protein in female rabbits. The modified H2A was highly immunogenic, eliciting high titer immunogen-specific antibodies, while the unmodified form was almost nonimmunogenic. Antibodies against standard carboxymethyllysine (CML) and pentosidine were detected in the immunized female rabbits, which demonstrates the immunogenic nature of AGEs (CML and pentosidine) as well. The results show both structural perturbation and AGEs have the capacity of triggering the immune system due to the generation of neoepitopes that render the molecule immunogenic. This study shows the presence of autoantibodies against 3-DG-modified H2A, CML, and pentosidine in the sera of type 2 diabetes patients having secondary complications. Autoantibodies against damaged H2A and AGEs may be significant in the assessment of initiation/progression of secondary complications in type 2 diabetes mellitus patients or may be used as a marker for early detection of secondary complications in diabetes.
Ключевые слова
Об авторах
J. Ashraf
Faculty of Applied Medical Sciences
Автор, ответственный за переписку.
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan
S. Abdullah
Faculty of Applied Medical Sciences
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan
S. Ahmad
Department of Biotechnology
Email: jmashraf@gmail.com
Индия, Lucknow
S. Fatma
Faculty of Science
Email: jmashraf@gmail.com
Индия, Varanasi
M. Baig
Department of Medical Biotechnology
Email: jmashraf@gmail.com
Республика Корея, Gyeongsan
J. Iqbal
Faculty of Medicine
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan
A. Madkhali
Faculty of Applied Medical Sciences
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan
A. Jerah
Faculty of Applied Medical Sciences
Email: jmashraf@gmail.com
Саудовская Аравия, Jazan
![](/img/style/loading.gif)